Zuprata: Ph III SAPPHIRE started

Clearside began the blinded, sham-controlled, U.S. Phase III SAPPHIRE trial to compare suprachoroidal Zuprata plus intravitreal Eylea aflibercept vs. Eylea alone in about 460 treatment-naïve patients....